BACKGROUND: Systemic chemotherapy typically converts previously unresectable liver metastases (LM) from @entity14 to curative intent resection in    15% of @entity1 . This European multicenter phase II trial tested whether hepatic artery infusion (HAI) with triplet chemotherapy and systemic cetuximab could increase this rate to 30% in previously treated @entity1 . @entity1 AND METHODS: @entity1 had unresectable LM from wt KRAS @entity14 . Main non-inclusion criteria were advanced extra @entity99 , prior HAI and grade 3 @entity16 . Irinotecan (180 mg/m(2)), @entity901 (85 mg/m(2)) and @entity1487 (2800 mg/m(2)) were delivered via an implanted HAI access port and combined with i.v. cetuximab (500 mg/m(2)) every 14 days. Multidisciplinary decisions to resect LM were taken after every three courses. The rate of macroscopic complete resections (R0 + R1) of LM, progression-free survival (PFS) and @entity1349 ( @entity1349 ) were computed according to intent to treat. RESULTS: The @entity1 population consisted of 42 @entity1 and 22 @entity1 , aged 33-76 years, with a median of 10 LM involving a median of six segments. Up to 3 extrahepatic lesions of <1 cm were found in 41% of the @entity1 . A median of six courses was delivered. The primary end point was met, with R0-R1 hepatectomy for 19 of the 64 previously treated @entity1 , 29.7% (95% confidence interval 18.5-40.9). Grade 3-4 @entity1398 (42.6%), @entity490 (26.2%), @entity1295 (18%) and @entity294 (16.4%) were frequent. Objective response rate was 40.6% (28.6-52.3). Median PFS and @entity1349 reached 9.3 (7.8-10.9) and 25.5 months (18.8-32.1) respectively. Those with R0-R1 hepatectomy had a median @entity1349 of 35.2 months (32.6-37.8), with 37.4% (23.6-51.2) alive at 4 years. CONCLUSION: The coordination of liver-specific intensive chemotherapy and surgery had a high curative intent potential that deserves upfront randomized testing. PROTOCOL NUMBERS: EUDRACT 2007-004632-24, NCT00852228.

Conversion to resection of liver metastases from XXXX with hepatic artery infusion of combined chemotherapy and systemic cetuximab in multicenter trial OPTILIV.

@entity1 :: ('9606', 'Species') :: ['women', 'patients', 'patient', 'PATIENTS', 'Participants', 'men'] @entity901 :: ('MESH:C030110', 'Chemical') :: ['oxaliplatin'] @entity16 :: ('MESH:D009422', 'Disease') :: ['neuropathy'] @entity294 :: ('MESH:D003967', 'Disease') :: ['diarrhea'] @entity1295 :: ('MESH:D005221', 'Disease') :: ['fatigue'] @entity1398 :: ('MESH:D009503', 'Disease') :: ['neutropenia'] @entity14 :: ('MESH:D015179', 'Disease') :: ['colorectal cancer'] @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'overall survival'] @entity490 :: ('MESH:D015746', 'Disease') :: ['abdominal pain'] @entity99 :: ('MESH:D056486', 'Disease') :: ['hepatic disease'] @entity1487 :: ('MESH:D005472', 'Chemical') :: ['5-fluorouracil']
@entity14 :: (MESH:D015179,Disease) :: ['colorectal cancer']
